As expected, we observed that like other driver gene fusions (e.g. ALK and ROS1), the majority of RET fusions are mutually exclusive with other primary driver alterations and the distribution of most common RET fusion partners [KIF5B 66%, CCDC6 18%, and others 16%] in NSCLC is similar to the existing RET registry studies on RET alterations8. Here, RET is linked to non-small cell lung carcinoma.